Retreatment with [177Lu]Lu-DOTATATE in neuroendocrine tumours: Outcomes in progression-free survival and toxicity – Our experience

#4475

Introduction: Multiple systemic treatments exist for advanced or metastatic NETs, including somatostatin analogues, targeted agents, chemotherapy, and peptide receptor radionuclide therapy (PRRT). PRRT has shown maximum benefit for response rate, progression-free survival (PFS), and overall survival (OS) with favourable toxicity.

Aim(s): Evaluate efficacy, PFS, and toxicity of patients post-retreatment (R-PRRT) with [177Lu]Lu-DOTATATE in disseminated, inoperable G1-G2 NETs.

Materials and methods: This retrospective study included G1 and G2 NET patients treated with 2 cycles of [177Lu]Lu-DOTATATE (R-PRRT) after responding to 4 initial PRRT cycles and showing later progression. Response was assessed with [68Ga]Ga-DOTATATE PET/CT or 99Tc-Tekrotyd SPECT/CT scans per RECIST 1.1, and toxicity via CTCAE 3.0 criteria.

Conference:

Presenting Author: Salcedo Cortes S

Authors: Salcedo Cortes S, Mari Hualde A, Ardila Manjarés E, Guzman Cruz A, Orcajo Rincón J,

Keywords: Neuroendocrine tumour (NET), Peptide receptor radionuclide therapy (PRRT), [177Lu]Lu-DOTATATE, Retreatment (R-PRRT), Toxicity, Progression-free survival (PFS), Overall survival (OS),